久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國(guó)diaDexus 
美國(guó)diaDexus位于加州Santa Clara，史克公司和Incyte制藥公司成立合資企業(yè).側(cè)重于應(yīng)用基因組序列數(shù)據(jù)研發(fā)新的診斷和治療產(chǎn)品。DiaDexus已使用基因組和生物信息學(xué)信息鑒定出數(shù)千疾病相關(guān)的分子靶目標(biāo)。最近，diaDexus有兩項(xiàng)診斷學(xué)候選產(chǎn)品處于亞臨床研究后期階段。
diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Company Overview
diaDexus was formed in 1997 as a joint venture by SmithKline Beecham and Incyte. SmithKline Beecham granted diaDexus an exclusive license to select diagnostic intellectual property, and Incyte contributed free access to its databases.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

diaDexus' lead product, the PLAC? Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events.

The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. Over 65 journals and conferences in peer-reviewed articles and abstracts, involving more than 100,000 subjects, highlight Lp-PLA2 as an important risk factor for cardiovascular disease.